Fenoldopam Versus Nitroprusside for the Treatment of Hypertensive Emergency

Abstract

Spanish

French

BACKGROUND

While sodium nitroprusside remains first-line therapy for hypertensive emergency (HEM), fenoldopam is increasingly being used because of its benign safety profile and potential renal protective effects.

OBJECTIVE

To compare the efficacy, safety, and cost of sodium nitroprusside versus fenoldopam for the treatment of HEM.

METHODS

This study was a retrospective analysis of consecutive patients with HEM admitted to a university-affiliated, level 1 trauma center from 1999 to 2001 and treated with either nitroprusside (n = 21) or fenoldopam (n = 22) for >30 minutes. Time to reach mean arterial pressure (MAP) goal, change in MAP over time, time to initiation of oral antihypertensive therapy, change in renal function, incidence of cyanide toxicity, and cost of therapy were compared between groups.

RESULTS

Demographic parameters were similar between groups, except renal failure, which was more prevalent in the fenoldopam group (10% vs 46%; p = 0.009). Neither the mean ± SD pretreatment MAP (nitroprusside 168 ± 19; fenoldopam 163 ± 19; p = 0.45), time to reach MAP goal (3.6 [0.4–30] vs 4 [1–22] h; p = 0.51), nor infusion duration (18 [0.7–113] vs 18 [3–74] h; p = 0.45) differed between the patient groups. Time to initiation of oral antihypertensive therapy was similar between nitroprusside- (4.5 h [0.5–22] and fenoldopam- (6.5 h [1–100] treated patients; p = 0.65). Additional intravenous antihypertensives were administered to 16 patients in each group (p = 0.80). Change in creatinine clearance and incidence of tachycardia did not differ between groups. No symptoms of cyanide toxicity were detected. Cost of drug therapy was greater with fenoldopam ($597.60, $199.20–6675.20); than nitroprusside ($2.66, $1.68–3.48; p < 0.001).

CONCLUSIONS

Treatment of HEM with fenoldopam appears to result in patient outcomes equivalent to those with nitroprusside but at a substantially higher cost. Further study is required to delineate the exact role of fenoldopam for treatment of HEM.

Keywords

fenoldopam hypertensive emergency nitroprusside

Get full access to this article

View all access options for this article.

References

1. Varon

, Marik

. The diagnosis and management of hypertensive crises. Chest 2000; 118: 214–27.

2. Mansoor

, Frishman

. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis 2002; 4: 358–71.

3. Oparil

, Aronson

, Deeb

, Epstein

, Levy

, Luther

, Fenoldopam: a new parenteral antihypertensive. Consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertension 1999; 12: 653–64.

4. Zampaglione

, Pascale

, Marchisio

, Cavallo-Perin

. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996; 27: 144–7.

5. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, National Institutes of Health. JAMA 2003; 289: 2560–72.

6. Friederich

, Butterworth

. Sodium nitroprusside: twenty years and counting. Anesth Analg 1995; 81: 152–62.

7. Rindone

, Sloane

. Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother 1992; 26: 515–9. Erratum: 1992; 26: 1160.

8. Pasch

, Schulz

, Hoopleshauser

. Nitroprusside-induced formation of cyanide and its detoxification with thiosulfate during deliberate hypotension. J Cardiovasc Pharmacol 1983; 5: 77–85.

9. Murphy

, Murray

, Shorten

. Fenoldopam—a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345: 1548–57.

10.

10. Panacek

, Bednarczyk

, Dunbar

, Foulke

, Holcslaw

. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med 1995; 2: 959–65.

11.

11. Elliott

, Weber

, Nelson

, Oliner

, Fumo

, Gretler

, Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990; 81: 970–7.

12.

12. Allaqaband

, Tumuluri

, Malik

, Gupta

, Volkert

, Shalev

, Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279–83.

13.

13. Knaus

, Draper

, Wagner

, Zimmerman

. APACHE II: a severity of disease classification system. Crit Care Med 1985; 10: 818–29.

14.

14. Cockcroft

, Gault

. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

15.

15. 2002 Red Book. Montvale, NJ: Medical Economics, 2002.

16.

16. Reisin

, Huth

, Nguyen

, Weed

, Gonzalez

. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 1990; 15 (suppl): I59–62.

17.

17. Bednarczyk

, White

, Munger

, Gonzalez

, Panacek

, Weed

, Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertension. Am J Cardiol 1989; 63: 993–6.

18.

18. White

, Halley

. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 1989; 149: 870–4.

19.

19. Mathur

, Sawn

, Lambrecht

, Anjum

, Fellman

, McGuire

, The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 2044–5.

20.

20. Shusterman

, White

. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993; 95: 161–8.